Philippe Chambon

Philippe Chambon discloses dealings in 3 companies, chiefly NxStage Medical, Inc., Auxilium Pharmaceuticals Inc and Epocrates Inc. We count 58 filings; the first trade dates from 24 May 2006 and the latest from 8 March 2011.

In open-market terms, that means 2 purchases worth €2.9M on one side and 15 sales worth €29.4M on the other. The net balance comes to €26.4M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 34 share grants and 1 option exercise. 2011 to date brings no purchases and 1 sale.

Most recently, on 10 March 2011, the filings show a transaction worth €11.7M in Auxilium Pharmaceuticals Inc. The clock since the last published purchase (15 June 2006) now reads 7,451 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.